Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Pressure BioSciences’ PCT platform features at major Australian cancer research centre

Wednesday, October 26, 2016 12:21
% of readers think this story is Fact. Add your two cents.

Pressure BioSciences, Inc. (OTCMKTS:PBIO) announced on Wednesday its featured participation in the recent opening of The ACRF International Centre for the Proteome of Human Cancer (“ProCan”), located in newly renovated laboratory facilities at the Children’s Medical Research Institute (“CMRI”) near Sydney, Australia.

PBI, the leader in the development and sale of broadly enabling pressure cycling technology (“PCT”)-based sample preparation solutions to the large and growing worldwide life sciences industry, said that in addition to itself, ProCan and CMRI scientists, presentations were made by other invitees, including representatives from SCIEX, Ilumina, Beckman-Coulter, and NextBio, as well as from Dr. Tiannan Guo of Professor Ruedi Aebersold’s lab at the world-renowned Institute of Molecular Systems Biology (Zurich, Switzerland).

Professor Aebersold is generally considered to be one of the leading proteomics scientists in the world.

ProCan expects to analyse a minimum of 10,000 cancer tumor samples per year over the next seven years with cutting-edge protein analysis instruments and other lab tools. It is anticipated that data from their studies will trigger discoveries illuminating causes of cancer, providing invaluable guidance on cancer treatment options and creating a new era in standard operating procedures applied in cancer testing laboratories worldwide.

“CMRI was recently named an official collaborator of the US National Cancer Institute’s “Cancer Moonshot” initiative, whose goal is to accelerate what would normally take ten years of cancer research into completion in the next five years,” said Dr. Nate Lawrence, Vice President of Sales and Marketing for PBI.

“We believe that the Cancer Moonshot initiative will strategically support and accelerate the field of precision (personalized) medicine through studies such as those planned at CMRI, which could lead to better identification, diagnosis, treatment, and prevention of cancer. We are proud to be a part of this very important and inspiring program.”

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.